DEI vs RARE · P/E 47, rev $507.5M vs rev $350.0M
Douglas Emmett Inc (DEI) versus Ultragenyx (RARE) — a side-by-side from cached financials, not a winner call.
Douglas Emmett Inc (DEI) is a reit - office company listed on US.
Ultragenyx (RARE) is a biotechnology company listed on US.
Latest reported DEI revenue for 2026-06-30 was $507.5M. Net income was -$5.2M. DEI currently screens at market cap $3.06B and trailing P/E 47.2.
Latest reported RARE revenue for 2026-06-30 was $350.0M. Net income was -$277.0M. RARE currently screens at market cap $2.79B.
DEI currently screens at market cap $3.06B and trailing P/E 47.2. RARE currently screens at market cap $2.79B.
Not investment advice. Open the DEI and RARE stock pages for the full models.
Not investment advice.